Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CLN-619 by Cullinan Therapeutics for Ovarian Cancer: Likelihood of Approval
CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
CLN-617 by Cullinan Therapeutics for Metastatic Melanoma: Likelihood of Approval
CLN-617 is under clinical development by Cullinan Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...
CLN-617 by Cullinan Therapeutics for Solid Tumor: Likelihood of Approval
CLN-617 is under clinical development by Cullinan Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
CLN-617 by Cullinan Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
CLN-617 is under clinical development by Cullinan Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
Risk adjusted net present value: What is the current valuation of Cullinan Therapeutics's CLN-619?
CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Metastatic Transitional (Urothelial) Tract...
CLN-978 by Cullinan Therapeutics for Follicular Lymphoma: Likelihood of Approval
CLN-978 is under clinical development by Cullinan Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
CLN-978 by Cullinan Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval
CLN-978 is under clinical development by Cullinan Therapeutics and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...